dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada Insights into the Roles of GLP-1, DPP-4, SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology GLP-1-RA and DPP-4 inhibitors in
Description
Marso SP, Daniels GH, BrownFrandsen K, et al
Zhang L, Li C, Zhu Q, Li N, Zhou H
15 In the SURPASS-1 study, tirzepatide monotherapy at increasing doses of 5, 10, and 15 mg resulted in significant weight loss of 7, 7.8, and 9.5 kg, respectively, at week 40 in patients with T2DM, compared with a 0.7 kg decrease with placebo
Patients currently using compounded semaglutide or tirzepatide should discuss transitioning to FDA approved formulations with their healthcare provider
